Jump to main content
Jump to site search

Issue 19, 2018
Previous Article Next Article

Applications of tumor chip technology

Author affiliations


Over the past six decades the inflation-adjusted cost to bring a new drug to market has been increasing constantly and doubles every 9 years – now reaching in excess of $2.5 billion. Overall, the likelihood of FDA approval for a drug (any disease indication) that has entered phase I clinical trials is a mere 9.6%, with the approval rate for oncology far below average at only 5.1%. Lack of efficacy or toxicity is often not revealed until the later stages of clinical trials, despite promising preclinical data. This indicates that the current in vitro systems for drug screening need to be improved for better predictability of in vivo outcomes. Microphysiological systems (MPS), or bioengineered 3D microfluidic tissue and organ constructs that mimic physiological and pathological processes in vitro, can be leveraged across preclinical research and clinical trial stages to transform drug development and clinical management for a range of diseases. Here we review the current state-of-the-art in 3D tissue-engineering models developed for cancer research, with a focus on tumor-on-a-chip, or tumor chip, models. From our viewpoint, tumor chip systems can advance innovative medicine to ameliorate the high failure rates in anti-cancer drug development and clinical treatment.

Graphical abstract: Applications of tumor chip technology

Back to tab navigation

Publication details

The article was received on 31 Mar 2018, accepted on 11 Aug 2018 and first published on 14 Aug 2018

Article type: Critical Review
DOI: 10.1039/C8LC00330K
Lab Chip, 2018,18, 2893-2912

  •   Request permissions

    Applications of tumor chip technology

    S. J. Hachey and C. C. W. Hughes, Lab Chip, 2018, 18, 2893
    DOI: 10.1039/C8LC00330K

Search articles by author